There is growing interest in the use of oxytocin (OT) as a potential treatment for alcohol and other substance-use disorders. OT is a neuropeptide that modulates adaptive processes associated with addiction including reward, tolerance, associative learning, memory, and stress responses. OT exerts its effects through interactions with the hypothalamic-pituitary-adrenal axis and multiple neurotransmitter systems including the dopamine mesolimbic reward and corticotrophin-releasing factor stress systems. The effects of OT on stress systems are of high interest, given the strong link between stress, drug use and relapse, and known dysregulation of hypothalamic-pituitary-adrenal-axis activity associated with substance-use disorders. At the same time, the OT system is itself altered by acute or chronic drug exposure. This review summarizes the preclinical and clinical literature on the OT system and its relevance to drug and alcohol addiction. In addition, findings from recent clinical trials conducted in participants with cocaine, cannabis, or alcohol use disorder are included and evidence that OT may help to normalize blunted stress responses, and attenuate withdrawal-associated hypercortisolism, negative mood, and withdrawal symptoms is summarized. Behavioural Pharmacology 27:640-648
Introduction
Oxytocin (OT) is a nine amino acid polypeptide hormone that acts through a specific receptor and is distributed widely in the central nervous system (CNS) and peripheral tissues (Gimpl and Fahrenholz, 2001) . OT is involved in the regulation and release of adenohypophyseal hormones including prolactin, adrenocorticotropin, gonadotropins, and corticotrophin-releasing factor (CRF). Initially, OT was believed to be primarily involved in sexual behaviors, female parturition, and lactation. Subsequent research has determined that OT is also involved in emotional regulation, pain, and stress, and modulates response to rewarding behaviors promoted by food, sex, and drugs (Meyer-Lindenberg et al., 2011; Onaka et al., 2012) . The comodulation of both stress and motivational processes is believed to be because of the important role of OT to shift salience to social, affiliative processes, both by increasing the salience itself of rewarding stimuli and/or by reducing stress, allowing for attention to social bonding (Baskerville and Douglas, 2010) . This is obviously relevant to addiction, where salience of drug stimuli overshadows motivation for social affiliation and where stress may trigger drug seeking and relapse (Sinha, 2008) . In the current review, we will focus on the role of the OT system in drug and alcohol addiction and highlight key findings to date on the use of intranasal OT to treat substance-use disorders (SUDs).
Oxytocin and stress
The influence of OT to dampen stress responses is important. Neuroendocrine pathways that modulate the response to stress include three interconnecting circuits: the hypothalamic-pituitary-adrenal (HPA) axis, the adrenomedullary system, and the extrahypothalamic CRF system. The HPA axis releases CRF from paraventricular (PVN) neurons within the hypothalamus, stimulating the synthesis and release of adrenocorticotropin by the anterior pituitary, which in turn stimulates the synthesis and release of corticosteroids (CORT) (cortisol in human and nonhuman primates and corticosterone in rodents) through the adrenal cortex. The sympathetic adrenomedullary system, which releases norepinephrine and epinephrine, and CRF expression in the extrahypothalamic brain regions including limbic regions, are key substrates involved in anxiety and other stress-related behaviors. Stress, defined as any stimulus that disrupts physiological homeostasis, triggers a cascade of adaptive responses involving any or all of these pathways to return the organism to homeostasis.
There is strong evidence from the preclinical literature that stress exposure is an important contributor to relapse. In rats and monkeys, acute stress enhances alcohol preference and reward (Funk et al., 2004) , and increased alcohol intake is correlated with stress-induced increases in CORT levels (Fahlke et al., 2000; Fish et al., 2008) . In addition, following repeated social stress exposure (e.g. defeat, low social rank, and maternal separation), rats and monkeys subsequently show greater alcohol intake compared with nonstressed cohorts (Fahlke et al., 2000; Cruz et al., 2008; Fish et al., 2008) . Current theories suggest that CORT release induced by stress augments drug reinforcement. Indeed, in rodents, CORT increases drug reward by increasing mesolimbic dopamine transmission (Piazza and Le Moal, 1996) , is self-administered itself at levels similar to those elicited by stress, and intracerebroventricular (ICV) infusions of CORT enhance the reinforcing effects of alcohol (Fahlke et al., 1996) .
Studies in laboratory animals have shown that OT has marked antistress effects. When administered centrally, OT decreases stress-induced increases in CORT levels (Lang et al., 1983; Windle et al., 1997; Neumann et al., 2000) and reduces stress-induced behaviors in rodent models of anxiety and depression (Arletti and Bertolini, 1987; Insel and Winslow, 1991; Windle, et al., 1997; Neumann et al., 2000) . At the same time, the endogenous OT system appears to be sensitive to stressors. In rats, exposure to acute stress increased OT levels in blood and in hypothalamic and extrahypothalamic brain regions (Lang et al., 1983; Neumann et al., 1998; Ebner et al., 2000; Ondrejcakova et al., 2010) and increased OT mRNA levels (Jezova et al., 1995) . Thus, OT appears to play a protective role in homeostatic regulation of stress responses and OT administration may attenuate the effects of stress on drinking/drug use and relapse (Uhart and Wand, 2009; Koob et al., 2014) .
Investigations in human participants are in line with the preclinical literature. When administered through the intranasal route, OT produces changes in measures of autonomic arousal and mood (MacDonald et al., 2011) , increased positive communication during couples' conflict discussions (Ditzen et al., 2009) , and improved recognition and processing of positive facial expressions (di Simplicio et al., 2009; Marsh et al., 2010; Lischke et al., 2012) . The antistress effects of OT have also been investigated using the Trier Social Stress Test, a wellvalidated laboratory procedure for induction of stress responses in human participants (Foley and Kirschbaum, 2010) . This test, which includes components of public speaking component and oral mental arithmetic, produces a robust increase in CORT and self-reported psychological stress and these effects are attenuated by OT (Heinrichs et al., 2003; Quirin et al., 2011; Simeon et al., 2011; de Oliveira et al., 2012; Kubzansky et al., 2012) . Consistent with an OT antistress hypothesis, a recent study that measured both OT and CORT after the TSST found that salivary OT levels increased immediately following social stress exposure before increases in salivary CORT (Jong et al., 2015) . Taken together, these data suggest that OT treatment may be useful to normalize the HPA axis and reduce stress-related physiological and subjective responses (e.g. anxiety, craving) that increase drug and alcohol use and trigger relapse. The endogenous oxytocin system and chronic drug use OT, the related peptide, vasopressin, and their respective receptors are highly conserved in evolution (Beets et al., 2012) . The OT receptor belongs to the rhodopsin-type (class 1) G protein-coupled receptor family and was cloned in 1992 (Kimura et al., 1992) . Studies in laboratory animals have shown that OT is synthesized in the magnocellular neurons of the PVN, supraoptic (SON), and accessory magnocellular nuclei of the hypothalamus and released into the bloodstream from axon terminals of these neurons, which are located in the posterior pituitary. Central release of OT occurs by two mechanisms (Ross and Young, 2009 ): (a) There is dendritic release from the PVN and SON in the hypothalamus (Ludwig and Leng, 2006) with passive diffusion to OT receptors, which are located throughout the brain (Gimpl and Fahrenholz, 2001) ; (b) more targeted direct release of OT occurs from nerve terminals of parvocellular neurons of the PVN, which project centrally to diverse regions including, among others, the olfactory bulb, tubercule, medial and central amygdala, lateral septum, hippocampus (HPC), brainstem, and spinal cord (Stoop, 2014) .
There is evidence that chronic exposure to drugs of abuse produces compensatory neuroadaptive changes in the endogenous OT system in specific brain regions involved in addiction processes. The direction of change is region specific. For example, OT receptor density in the rodent amygdala and hypothalamus increases following chronic administration of methamphetamine, cocaine, and morphine (Zanos et al., 2014a (Zanos et al., , 2014b Georgiou et al., 2015) , whereas in the HPC, decreased levels of OT and/or OT receptor density were reported following chronic administration of cocaine (Sarnyai and Kovacs, 1994) or morphine (Zanos et al., 2014a) . Chronic self-administration of methamphetamine also results in decreased OT receptor immunoreactive fibers in the nucleus accumbens (NAc) core compared with yoked controls . Chronic exposure to Δ 9 -tetrahydrocannabinol in rats downregulates OT mRNA expression in the NAc and ventral tegmental area (Butovsky et al., 2006) . Chronic administration of morphine to rats alters brain OT expression differentially with a decrease in OT mRNA in the SON and NAc and an increase in the ventral tegmental area and locus coeruleus (You et al., 2000) .
To date, studies in humans are limited to post-mortem autoradiography studies and examination of circulating OT. In alcoholic individuals, plasma OT levels were decreased (Marchesi et al., 1997) and OT immunoreactivity was decreased in the hypothalamus post mortem (Sivukhina et al., 2006) . A final common pathway of drugs and alcohol is activation of stress as well as reward processing (Koob et al., 2014) . It is unknown how activation of either of these pathways results in a decrease in OT synthesis, especially when in general, stressors are associated with an activation of OT systems (Light et al., 2004; Hoge et al., 2008; Taylor et al., 2010; Jong et al., 2015) . Apart from the effect of the drugs of abuse on the endogenous OT system, environmental factors such as stress and traumatic social experiences all contribute toward the emergence of individual differences in the endogenous OT system that may then contribute toward the development of addiction (Buisman-Pijlman et al., 2014) . Overall, it is also unknown whether administration of exogenous OT will reverse these changes in OT synthesis created by exposure to drugs of abuse and whether this would translate into reversal of addictive behaviors or whether administration of OT can prevent the development of addiction after exposure to environmental risk factors. Finally, the relationship between peripheral OT levels in plasma and central levels of OT is not known, but they are thought to be regulated separately (Ludwig and Leng, 2006) ; therefore, studies that use plasma OT as a surrogate for central OT function are of limited value.
Preclinical studies examining the effect of oxytocin on drug-seeking behavior
Interest in OT as a modulator of the neurobehavioral response to alcohol and other drugs of abuse stems from work carried out in the 1970s by de Wied and colleagues (Bohus et al., 1978) , who showed that hypophyseal hormones modulate learning and memory, with OT generally exerting an inhibitory effect. As current theories conceptualize addiction as a form of maladaptive learning, a large number of preclinical studies in rodents have investigated the effect of OT on various drug-related behaviors to determine whether OT could reverse the neuroadaptations occurring with repeated drug and alcohol use (Sarnyai and Kovacs, 1994) .
As the majority of the published literature has focused on the effects of OT on behavioral and neurochemical responses to opiates, psychostimulants, and alcohol, we summarize these studies below.
Opiates
Early preclinical studies focused on the effect of OT to modulate the development of acute and chronic tolerance to the analgesic effect of morphine and heroin is reduced with a single dose of OT, whereas higher doses of OT are required to reduce established chronic tolerance (Kovacs et al., 1984 (Kovacs et al., , 1985b . Further, administration of an OT receptor antagonist inhibits this effect on tolerance, suggesting that the endogenous OT system opposes the development of acute tolerance . Moreover, this effect appears to be centrally mediated as ICV injections of OT are more potent in their action to inhibit acute and chronic tolerance as are localized injections into the HPC or NAc or administration of dipeptides derived from the C-terminal OT portion (Kovacs et al., 1985a (Kovacs et al., , 1985b . OT also delays naloxone-induced withdrawal symptoms in a dosedependent manner (Kovacs et al., 1984 (Kovacs et al., , 1985b .
With respect to self-administration behavior, OT decreases both the acquisition and the maintenance of heroin self-administration (Kovacs et al., 1985b) . This effect is reproduced with an injection of OT into the NAc or HPC (Ibragimov et al., 1987) . However, the effect of OT on heroin self-administration was tested with only one dose of heroin (Kovacs et al., 1985a) ; therefore, without dose-response information, it is not possible to determine whether OT was inhibiting or potentiating the effects of heroin. OT administered ICV increased the expression of morphine-induced conditioned place preference (Moaddab et al., 2015) . This effect may be explained in part by a well-described effect of acute morphine to inhibit OT cell firing in the hypothalamus, with tolerance developing to this effect with repeated administration of morphine (Bicknell et al., 1988) . During morphine withdrawal, there is a rebound hyperexcitation of these cells with increased release of OT (Bicknell et al., 1988) . In light of this effect, administration of OT after conditioning with repeated injections of morphine may signal a withdrawal state, which then drives the increased conditioned place preference observed in this study (Moaddab et al., 2015) . Further evidence that OT is involved in withdrawal from morphine is that peripheral administration of carbetocin, an OT analog, inhibits the development of anxiety and depressive behaviors and improves social behaviors during morphine withdrawal, as well as preventing stress-induced reinstatement of conditioned place preference for morphine (Zanos et al., 2014a (Zanos et al., , 2014b . These results are consistent with those reported by Qi et al. (2009) , who reported an inhibitory effect of OT on stress-primed reinstatement of conditioned place preference for methamphetamine.
In summary, there is evidence that OT inhibits tolerance to opiates, and reduces opiate self-administration, and stressinduced reinstatement of extinguished opiate-taking behaviors. At the same time, it is not clear whether changes in OT levels during early drug withdrawal have a positive or a negative impact on withdrawal severity and drug-taking behaviors. The increase in endogenous OT release during withdrawal may drive opiate-seeking behavior in the withdrawal state, but may also ameliorate behavioral disturbances that occur during opiate withdrawal.
Psychostimulants
Early preclinical work examined the effects of OT on psychostimulant-related behaviors. For example, OT reduced locomotor hyperactivity and stereotyped behaviors induced by cocaine Sarnyai et al., 1990 Sarnyai et al., , 1991 , but not amphetamine (Kovacs et al., 1985b; Sarnyai and Kovacs, 1994) .
More recent preclinical work on psychostimulants has focused on methamphetamine, probing the mechanism underlying the largely inhibitory effect of OT on locomotor hyperactivity, self-administration, and conditioned place preference (Qi et al., 2008 (Qi et al., , 2009 Carson et al., 2010a Carson et al., , 2010b Baracz et al., 2012; Baracz and Cornish, 2013; Han et al., 2014; Bahi, 2015) . The recent studies examining the mechanism of drug-induced, stressinduced, or cue-induced reinstatement of conditioned place preference or drug-seeking behavior on balance show that OT has an effect on all of these animal models, with some evidence that the mesocorticolimbic system is involved in modulating these effects. It should be noted, however, that there are inconsistent results with respect to the direct involvement of the OT receptor in the reported inhibitory effects; these studies are reviewed below.
One preclinical paradigm, conditioned place preference (or aversion), involves pairing repeated drug administration with a specific environment and association of a different environment with the absence of the drug to measure the rewarding effects of the test drug. OT has been reported to reduce the acquisition, but not the expression, of methamphetamine-induced conditioned place preference (Qi et al., 2009) . This suggests that OT reduces the rewarding effect of methamphetamine and perhaps does less to inhibit memory retrieval processes. The potential application of OT as a preventative treatment for the development of addictive behaviors was examined by Hicks et al. (2016) , who treated female rats with daily systemic OT during adolescence and found a reduction in responding for methamphetamine under a progressive ratio schedule and reduced reinstatement to a methamphetamine prime, as well as higher plasma OT levels, compared with untreated rats.
Reinstatement models of drug relapse include both operant self-administration models and place-conditioning models. OT studies report mixed results depending on the reinstatement paradigm used (conditioned place preference vs. self-administration). OT decreases both stress-primed and cue-primed (but not drug-primed) reinstatement of methamphetamine-conditioned place preference (Qi et al., 2009; Han et al., 2014; Morales-Rivera et al., 2014) . The effect of OT to reduce stress-primed (but not drug-primed) reinstatement of conditioned place preference for methamphetamine was accompanied by a reduction in medial prefrontal cortical (mPFC) glutamate levels as measured by microdialysis (Qi et al., 2009 ). This effect was reversed by an OT antagonist. The effect of OT on stress priming of the reinstatement of conditioned place preference was further explored by microinjecting OT into the dorsal HPC and mPFC (Han et al., 2014) . Stress-induced reinstatement was inhibited by OT injected into the mPFC and reversed with an OT receptor antagonist. It was also inhibited when injected into the dorsal HPC, albeit at a higher dose, and this effect was not reversed by an OT receptor antagonist.
Local administration of OT into the subthalamic nucleus or the NAc core decreased methamphetamine-induced reinstatement of self-administration (Baracz et al., 2015 (Baracz et al., , 2016b . These effects were not reversed with coadministration of an OT antagonist suggesting that OT does not directly directly modulate methamphetamine relapse behavior, and that other receptor systems are likely involved. Zhou et al. (2014) examined the effect of OT on cocaine self-administration under different reinforcement schedules and conditions of drug availability, as well as cue-primed and drug-primed reinstatement of cocaineseeking and sucrose-seeking behavior. OT dose dependently reduced cocaine self-administration under conditions of increasing motivational demands (i.e. progressive ratio schedules) and reduced the maximal amount of work (breakpoint) for a cocaine injection. OT also reduced the effects of cocaine-induced or cueinduced reinstatement of extinguished cocaine selfadministration behavior (i.e. cocaine seeking) and reversed cocaine-induced changes in glutamate receptor function (Zhou et al., 2015) .
Alcohol
Recent preclinical data show that administration of OT may disrupt behavioral and brain neuroadaptive changes associated with long-term alcohol exposure (Sarnyai and Kovacs, 1994; McGregor and Bowen, 2012) . Early studies with OT focused on the ability of the peptide to reduce or reverse tolerance. A single dose of OT had no effect on tolerance; however, repeated dosing before alcohol decreased tolerance to the hypothermic response to alcohol (Szabo et al., 1985 (Szabo et al., , 1989 . Interestingly, once tolerance had developed, administration of OT had no modulatory effect on tolerance (Szabo et al., 1985) . In alcohol-naive or alcohol-dependent mice, a single dose of OT had no effect on the severity of picrotoxin-induced seizures . In contrast, OT, administered before alcohol daily resulted in a milder intensity of alcohol-withdrawal seizures precipitated by picrotoxin , suggesting rapid reversal of tolerance. In addition, OT reduces the development of rapid tolerance to the hypnotic, myorelaxant effects of alcohol (Rigter et al., 1980; Pucilowski et al., 1985; Szabo et al., 1985 Szabo et al., , 1989 , and produces a prolonged attenuation of alcohol-withdrawal symptoms Kovacs et al., 1998; McGregor and Bowen, 2012) .
For self-administration, large doses of OT administered either peripherally or centrally have no effect on alcohol drinking using a two-bottle free-choice paradigm (Peters et al., 2013) . However, McGregor and Bowen (2012) found that a single dose of OT, 1 mg/kg, reduced preference for an alcoholic beverage compared with a nonalcoholic sweet solution and this effect lasted for up to 6 weeks. Further, OT treatment for 2 weeks before the introduction of a two-bottle choice paradigm also resulted in a significantly lower alcohol preference in OT-treated compared with control rats. MacFadyen et al. (2016) recently reported that OT at lower doses (0.1-0.5 mg/kg, intraperitoneally) administered systemically reduced alcohol self-administration. In a chronic intermittentaccess model, OT administered ICV acutely similarly reduced ethanol self-administration and also blocked ethanol-induced dopamine release in the NAc in both ethanol-naive and chronically exposed rats (Peters et al., 2016) , highlighting a possible mechanism for the behavioral effect observed.
Consistent with these results, administration of the OT receptor agonist carbetocin or genetic overexpression of OT receptors in the NAc through a lentiviral vector decreased acquisition and alcohol-primed reinstatement of conditioned place preference and increased rates of extinction (Bahi, 2015) . However, although the OT receptor seems to be involved in the rewarding properties of ethanol and this appears to involve the ventral striatum, the sedative and ataxic effects of alcohol do not appear to be mediated by the OT receptor (Bowen et al., 2015) .
Overall, there is evidence that OT, administered systemically or centrally, reduces self-administration of opiates, cocaine, and alcohol and reinstatement of responding induced by exposure to drug cues and stress. The mechanisms seem to involve the midbrain dopaminergic as well as medial prefrontal glutamatergic pathways.
Human studies of oxytoxin in alcohol and drug dependence There are relatively few human studies that have examined the effects of OT in individuals with alcohol and drug dependence. Heavy alcohol drinking is associated with dysregulation of HPA-axis activity, as shown by episodes of hypercortisolism between drinking bouts and a blunted CORT response to stress during early abstinence (Kemper et al., 1990; Wand and Dobs, 1991; Errico et al., 1993; Vescovi et al., 1997; Boschloo et al., 2011) . A blunted CORT response has been associated with increased anxiety and craving during acute abstinence and subsequent relapse to heavy drinking (Walter et al., 2006; Higley et al., 2011; Sinha et al., 2011) .
The potential of OT as a treatment for alcohol use disorder is highlighted by a recent small clinical trial (n = 11) in alcohol-dependent individuals. All participants underwent alcohol detoxification with PRN administration of the benzodiazepine lorazepam and were concurrently randomized to intranasal OT (24 IU twice daily for 3 days) or placebo during the withdrawal period. Participants randomized to OT had significantly fewer alcohol-withdrawal symptoms and required less symptom-triggered lorazepam for withdrawal symptoms compared with placebo (Pedersen et al., 2013) . Relating this finding to the early preclinical literature, the authors posit that the mechanism of this effect might relate to rapid reversal of tolerance by OT.
In the context of stress provocation using the Trier Social Stress Test, pretreatment with a single dose of OT (40 IU) reduced stress-induced craving and anxiety in cannabis-dependent individuals (McRae-Clark et al., 2013) . This was a between-participants double-blind placebo-controlled study (N = 16) in which OT reduced marijuana craving and stress scores after the session, but did not alter anxiety scores. Also, using the Trier Social Stress Test, Flanagan et al. (2015) examined the effect of OT on the cortisol response in 31 cocaine-dependent individuals. Participants were randomized to receive a single dose of OT (40 IU) or placebo before the Trier Social Stress Test. There was a significant relationship between the cortisol response after social stress and the degree of adverse childhood experiences for those on placebo, which was absent in the OT group (Flanagan et al., 2015) . Our group reported analogous results in cocaine-dependent in-patients, where the significant positive relationship between state anger and cueinduced craving that was observed in the placebo condition was absent in the OT condition. This was a single OT dose (24 IU) crossover study in cocaine-dependent in-patients (N = 23) assessing the effect of OT on desire to use, cue-induced craving, and monetary reward tasks. OT, compared with placebo, increased participants' desire to use, but had no effect on cue-induced cocaine craving .
These studies require replication as they are small and largely exploratory, with different OT dosing and patients who were all drug or alcohol dependent, but were in different stages of treatment. Specifically, the alcoholic patients were in withdrawal, the marijuana patients were actively using, and the cocaine-dependent patients in one of the studies were abstinent and in a controlled environment. There are also no controlled studies examining the effects of OT on human drug selfadministration or subjective effects in the laboratory. Clearly, more human research is needed to determine whether the positive signals observed in animal models are replicated in humans. In addition, very little is known about the pharmacokinetics of OT, the effect of repeated OT dosing on behavioral outcomes over time, or the optimal dosing interval.
Brain penetrance of exogenously administered oxytocin and dosing
A key issue is whether systemically administered OT gains access to the CNS directly or whether it exerts its effects through an intermediate pathway. There is considerable controversy on the subject (Leng and Ludwig, 2016) . This notwithstanding, peptides have been shown to cross the blood-brain barrier in small amounts either by extracellular active transport or by transcellular diffusion (Banks, 2015) . In humans, the time course of cerebrospinal fluid (CSF) levels of OT and vasopressin, following their intranasal delivery, is consistent with extracellular transport as elevated CSF levels are detected 20-80 min after delivery (Born et al., 2002; Striepens et al., 2013) . In similar studies, OT reached peak levels in plasma 30-40 min after intranasal administration (Lundin et al., 1986; Burri et al., 2008; Gossen et al., 2012) . The relevance of circulating blood levels is unclear, given the considerable individual differences in OT levels in plasma (area under the curve, peak) (Gossen et al., 2012) and the lack of correlation between plasma and CSF levels (Striepens et al., 2013; Freeman et al., 2016) . It is clear, however, that intranasal administration of OT results in elevated CSF levels of OT in humans (Born et al., 2002; Striepens et al., 2013) , nonhuman primates (Chang et al., 2012; dal Monte et al., 2014; Modi et al., 2014; Freeman et al., 2016) , and rodents . It is not known whether the elevation in CSF OT after systemic administration is because of the administered peptide gaining access to the CSF or whether there is a feed-forward effect stimulated by either peripheral or centrally mediated mechanisms (Ermisch et al., 1985; Carson et al., 2010a Carson et al., , 2010b . Further, it is also not clear whether the peptide delivered reaches the CNS and whether it does so as an intact peptide.
The utility and feasibility of administration of intranasal OT as a medication is supported by its success in early clinical trials for the treatment of behavioral deficits associated with other neuropsychiatric disorders such as schizophrenia (Pedersen et al., 2011) , social anxiety (Labuschagne et al., 2010) , autism (Hollander et al., 2003) , and Prader-Willi syndrome (Tauber et al., 2011) . The dose of OT used has varied across studies and clinical trials. Most studies have used 24 IU OT (MacDonald et al., 2011) , although 40 IU OT was effective in cognition and stress studies (Ditzen et al., 2009; Simeon et al., 2011; Krueger et al., 2013; Leknes et al., 2013) . The side effects of OT generally appear to be minimal. For example, a recent meta-analysis of the safety and side effects of intranasal OT, drawn from 38 randomized trials, concluded that OT produces no reliable side effects and is not associated with adverse outcomes when delivered at an 18-40 IU/dose for short-term use in controlled research (MacDonalds et al., 2011) . In addition, doses as high as 320 IU/day OT have been administered safely to human participants, without reports of adverse events (Epperson et al., 1996; Ohlsson et al., 2005) .
Conclusion and future directions
Clinically, OT is an attractive candidate for the treatment of SUDs. OT exerts effects through interactions with multiple neurotransmitter systems including the dopamine mesolimbic reward, the HPA axis, and CRF stress systems. It also has low abuse liability and an excellent safety profile, as well as no detectable psychoactive actions. In most human studies, participants could not discriminate between placebo and active drug (OT) (MacDonald et al., 2011) . The possibility of OT remediating social deficits in drug-addicted and alcoholaddicted patients has been proposed, given the results of studies in social-cognitive neuroscience using OT (Meyer-Lindenberg et al., 2011) . Indeed, there are now multiple clinical trials underway further exploring the efficacy of OT for the treatment of SUD for marijuana (NCT01827332), cocaine (NCT01573273), alcohol (NCT 02407340; NCT02251912; NCT02058251), opioids (NCT 02548728), and tobacco (NCT02595749). Although some findings appear to be positive, caution should be exercised given the context-dependent and person-dependent effect of OT . Current thinking is that, in addition to its antistress effects, OT may facilitate the effects of dopamine (Insel, 2003) , which is involved in the reinforcing properties of drugs as well as conditioned responses to drugs (Volkow et al., 2006; Lee et al., 2014) . Because of this effect, exogenous OT may exacerbate some drug-related behaviors in individuals with SUD. One recent study did report that OT worsened some drugrelated behaviors . At the same time, the growing literature over the last 30 years investigating the effect of OT on neurobehavioral responses to drugs of abuse and alcohol remains promising.
To move the field forward, several important issues must be addressed in future research. First, the mechanism of action underlying the observation of reduced drug and ethanol self-administration and reinstatement in various contexts is still unknown. Additional studies in both laboratory animals and humans are needed. Second, OT itself has a short half-life McGregor and Bowen, 2012) , which raises concerns of actual clinical utility. Future investigations should examine the pharmacodynamic effects of OT, which are surprisingly long in some studies. Third, given the sex differences in the OT system and in addiction-related behaviors and the growing literature on sex-specific drug effects, it is critical that OT studies include both sexes to determine whether there are sex-specific effects. Fourth, the brain penetrance of the exogenously delivered peptide remains an unanswered question and should be explored fully. Finally, investigations with nonpeptide OT receptor agonists are also needed as this may lead to the development of medications with a longer half-life and less frequent administrations, therefore maximizing patients' treatment compliance. by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) R21 AA022679 (PI: Elise M. Weerts).
